

A Modular Approach to Marine Macrolide Construction. 3. Enantioselective Synthesis of the C1–C28 Sector of Spongistatin 1 (Altohyrtin A)


Dmitry Zuev and Leo A. Paquette*

Evans Chemical Laboratories, The Ohio State University, Columbus, Ohio 43210

paquette.1@osu.edu

Received January 5, 2000

ABSTRACT



A completely stereocontrolled approach to assembly of the major C1–C28 subunit of spongistatin 1 (altohyrtin A) is described. Key steps included the control of two asymmetric aldols by means of Fujita–Nagao (chiral *N*-acyl-1,3-thiazolidine-2-thione auxiliary) and Mukaiyama ($\text{BF}_3 \cdot \text{OEt}_2$ -promoted enolsilane coupling) protocols in complex settings.

The spongipyran marine macrolides, designated as the spongistatins,¹ altohyrtins,² and cinachyrolides³ by their independent discoverers, are currently the most potent antineoplastic agents identified. The remarkable subnanomolar cytotoxicity exhibited by these sponge metabolites against several cancer cell lines,⁴ in combination with their

very limited supply, has prompted several groups to undertake synthetic activity in this area.^{5–18} Our early efforts have culminated in the concise stereocontrolled construction of both the C1–C12 (AB)¹⁹ and C17–C28 (CD) spiroacetal sectors.²⁰ We now describe an efficient means for tethering

(1) (a) Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R.; Schmidt, J. M.; Hooper, J. N. A. *J. Org. Chem.* **1993**, *58*, 1302. (b) Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R. *J. Chem. Soc., Chem. Commun.* **1993**, 1166. (c) Pettit, G. R.; Herald, C. L.; Cichacz, Z. A.; Gao, F.; Schmidt, J. M.; Boyd, M. R.; Christie, N. D.; Boettner, F. E. *J. Chem. Soc., Chem. Commun.* **1993**, 1805. (d) Pettit, G. R.; Cichacz, Z. A.; Herald, C. L.; Gao, F.; Boyd, M. R.; Schmidt, J. M.; Hamel, E.; Bai, R. *J. Chem. Soc., Chem. Commun.* **1994**, 1605. (e) Pettit, G. R. *Pure Appl. Chem.* **1994**, *66*, 2271.

(2) (a) Kobayashi, M.; Aoki, S.; Kitagawa, I. *Tetrahedron Lett.* **1994**, *35*, 1243. (b) Kobayashi, M.; Aoki, S.; Sakai, H.; Kawazoe, K.; Kihara, N.; Sasaki, T.; Kitagawa, I. *Tetrahedron Lett.* **1993**, *34*, 2795. (c) Kobayashi, M.; Aoki, S.; Sakai, H.; Kihara, N.; Sasaki, T.; Kitagawa, I. *Chem. Pharm. Bull.* **1993**, *41*, 989. (d) Kobayashi, M.; Aoki, S.; Gato, K.; Kitagawa, I. *Chem. Pharm. Bull.* **1996**, *44*, 2142.

(3) Fusetani, N.; Shinoda, K.; Matsunaga, S. *J. Am. Chem. Soc.* **1993**, *115*, 3977.


(4) (a) Bai, R.; Cichacz, Z. A.; Herald, C. L.; Pettit, G. R.; Hamel, E. *Mol. Pharmacol.* **1993**, *44*, 757. (b) Bai, R.; Taylor, G. F.; Cichacz, Z. A.; Herald, C. L.; Kepler, J. A.; Pettit, G. R.; Hamel, E. *Biochemistry* **1995**, *34*, 9714.

(5) (a) Evans, D. A.; Coleman, P. J.; Dias, L. C. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 2738. (b) Evans, D. A.; Trotter, B. W.; Côté, B.; Coleman, P. J. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 2741. (c) Evans, D. A.; Trotter, B. W.; Côté, B.; Coleman, P. J.; Dias, L. C.; Tyler, A. N. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 2744. (d) Evans, D. A.; Trotter, B. W.; Coleman, P. J.; Côté, B.; Dias, L. C.; Rajapakse, H. A.; Tyler, A. N. *Tetrahedron* **1999**, *55*, 8671.

(6) (a) Guo, J.; Duffy, K. J.; Stevens, K. L.; Dalko, P. I.; Roth, R. M.; Hayward, M. M.; Kishi, Y. *Angew. Chem., Int. Ed.* **1998**, *37*, 187. (b) Hayward, M. M.; Roth, R. M.; Duffy, K. J.; Dalko, P. I.; Stevens, K. L.; Guo, J.; Kishi, Y. *Angew. Chem., Int. Ed.* **1998**, *37*, 192.


(7) (a) Claffey, M. M.; Heathcock, C. H. *J. Org. Chem.* **1996**, *61*, 7646. (b) Hayes, C. J.; Heathcock, C. H. *J. Org. Chem.* **1997**, *62*, 2678. (c) Ott, G. R.; Heathcock, C. H. *Org. Lett.* **1999**, *1*, 1475. (d) Claffey, M. M.; Hayes, C. J.; Heathcock, C. H. *J. Org. Chem.* **1999**, *64*, 8267.

Scheme 1



^a SEMCl, (*i*-Pr)₂NEt, Bu₄NI, THF, rt, 24 h (95%). ^b (*i*-Bu)₂AlH, CH₂Cl₂, -78 °C, 45 min (98%). ^c TPAP, NMO, 4 Å MS, CH₂Cl₂, rt, 1 h (96%). ^d MeMgBr, THF, Et₂O, -78 to 0 °C, 2.5 h (93%). ^e TBSOTf, (*i*-Pr)₂NEt, CH₂Cl₂, -40 to 0 °C (93%). ^f DDQ, CH₂Cl₂-H₂O (16:1), rt, 1 h (90%). ^g I₂, PPh₃, imidazole, benzene, rt, 1.5 h (82%). ^h KCN, DMF, 65 °C, 36 h (quant). ⁱ (*i*-Pr)₂AlH, CH₂Cl₂, -78 °C, 20 min. ^j EtMgBr, Et₂O, -78 to 0 °C, 3 h (74% for two steps). ^k TPAP, NMO, 4 Å MS, CH₂Cl₂, rt, 9 h (99%).

these structurally complex building blocks via an enantioselective scheme designed to ultimately access spongistatin 1 (1, corresponds to althohyrtin A).



One phase of the convergent assembly began with 2, an alcohol readily obtained via the thermodynamically controlled spirocyclization described previously¹⁹ (Scheme 1). The remaining hydroxyl group was transformed into its SEM ether²¹ in advance of Dibal-H reduction to give 3b. Subsequent perruthenate oxidation²² gave ketone 4, which re-

sponded to the action of methylmagnesium bromide very predominantly by way of equatorial attack to furnish 5a in 93% yield. The resulting axial disposition and tertiary nature of the OH substituent in this intermediate required recourse to *tert*-butyldimethylsilyl triflate²³ for protection purposes. With 5b in hand, the acquisition of alcohol 5c proceeded without event. Homologation of the side chain in 5c began with cyanide ion displacement on iodide 6a. To skirt potential complications arising from β -elimination within 6b, this nitrile was directly transformed into ethyl ketone 8 by sequential low-temperature Dibal-H reduction, 1,2-addition


- (8) (a) Paterson, I.; Oballa, R. M.; Norcross, R. D. *Tetrahedron Lett.* **1996**, 37, 8581. (b) Paterson, I.; Keown, L. E. *Tetrahedron Lett.* **1997**, 38, 5727. (c) Paterson, I.; Gibson, K. R.; Oballa, R. M. *Tetrahedron Lett.* **1996**, 37, 8585. (d) Paterson, I.; Oballa, R. M. *Tetrahedron Lett.* **1997**, 38, 8241. (e) Paterson, I.; Wallace, D. J.; Gibson, K. R. *Tetrahedron Lett.* **1997**, 38, 8911. (f) Paterson, I.; Wallace, D. J.; Oballa, R. M. *Tetrahedron Lett.* **1998**, 39, 8545.
- (9) (a) Smith, A. B., III.; Zhuang, L.; Brook, C. S.; Boldi, A. M.; McBriar, M. D.; Moser, W. H.; Murase, N.; Nakayama, K.; Verhoest, P. R.; Lin, Q. *Tetrahedron Lett.* **1997**, 38, 8667. (b) Smith, A. B., III.; Zhuang, L.; Brook, C. S.; Lin, Q.; Moser, W. H.; Trout, R. E. L.; Boldi, A. M. *Tetrahedron Lett.* **1997**, 38, 8671. (c) Smith, A. B., III.; Lin, Q.; Nakayama, K.; Boldi, A. M.; Brook, C. S.; McBriar, M. D.; Moser, W. H.; Sobukawa, M.; Zhuang, L. *Tetrahedron Lett.* **1997**, 38, 8675.

- (10) (a) Hermitage, S. A.; Murphy, A.; Roberts, S. M. *Bioorg. Med. Chem. Lett.* **1998**, 8, 1635. (b) Hermitage, S. A.; Roberts, S. M.; Watson, D. J. *Tetrahedron Lett.* **1998**, 39, 3567. (c) Kary, P. D.; Roberts, S. M.; Watson, D. J. *Tetrahedron: Asymmetry* **1999**, 10, 213. (d) Kary, P. D.; Roberts, S. M. *Tetrahedron: Asymmetry* **1999**, 10, 217.
- (11) Fernandez-Megia, E.; Gourlaouen, N.; Ley, S. V.; Rowlands, G. J. *Synlett* **1998**, 991.
- (12) Micalizio, G. C.; Roush, W. R. *Tetrahedron Lett.* **1999**, 40, 3351.
- (13) Lemaire-Audoire, S.; Vogel, P. *Tetrahedron Lett.* **1998**, 39, 1345.
- (14) Crimmins, M. T.; Washburn, D. G. *Tetrahedron Lett.* **1998**, 39, 7487.
- (15) (a) Zemribo, R.; Mead, K. T. *Tetrahedron Lett.* **1998**, 39, 3891. (b) Zemribo, R.; Mead, K. T. *Tetrahedron Lett.* **1998**, 39, 3895.
- (16) Dunkel, R.; Treu, J.; Hoffmann, H. M. R. *Tetrahedron: Asymmetry* **1999**, 10, 1539.
- (17) Terauchi, T.; Nakata, M. *Tetrahedron Lett.* **1998**, 39, 3795.
- (18) For a recent overview of the field, consult Pietruszka, J. *Angew. Chem., Int. Ed.* **1998**, 37, 2629.
- (19) Paquette, L. A.; Zuev, D. *Tetrahedron Lett.* **1997**, 38, 5115.
- (20) Paquette, L. A.; Braun, A. *Tetrahedron Lett.* **1997**, 38, 5119.
- (21) Lipshutz, B. H.; Pegram, J. J. *Tetrahedron Lett.* **1980**, 21, 3343.
- (22) Griffith, W. P.; Ley, S. V. *Aldrichimica Acta* **1990**, 23, 13.
- (23) Corey, E. J.; Cho, H.; Rücker, C.; Hua, D. H. *Tetrahedron Lett.* **1981**, 22, 3455.
- (24) Fujita, E.; Nagao, Y. *Adv. Heterocycl. Chem.* **1989**, 1.
- (25) Nagao, Y.; Nagase, Y.; Kumagai, T.; Matsunaga, H.; Abe, T.; Shimada, O.; Hayashi, T.; Inoue, Y. *J. Org. Chem.* **1992**, 57, 4243.
- (26) Nagao, Y.; Hagiwara, Y.; Kumagai, T.; Ochiai, M.; Inoue, T.; Hashimoto, K.; Fujita, E. *J. Org. Chem.* **1986**, 51, 2391.
- (27) Pappo, R.; Allen, D. S., Jr.; Lemieux, R. U.; Johnson, W. S. *J. Org. Chem.* **1956**, 21, 478.
- (28) Nahm, S.; Weinreb, S. M. *Tetrahedron Lett.* **1981**, 22, 3815.
- (29) Masamune, S.; Ellingboe, J. W.; Choy, W. *J. Am. Chem. Soc.* **1982**, 104, 5526.
- (30) Evans, D. A.; Dart, M. J.; Duffy, J. L.; Yang, M. G. *J. Am. Chem. Soc.* **1996**, 118, 4322.

of ethylmagnesium bromide to the resulting aldehyde, and perruthenate oxidation.

Chiral *N*-acyl-1,3-thiazolidine-2-thiones have seen limited use for controlling asymmetric induction in aldol condensations.²⁴ When employed with tin(II) triflate and *N*-ethylpiperidine as promoters, *Z*-enolates are generated,²⁵ chelated transition states are kinetically favored,²⁶ and syn products appear to be formed with excellent diastereoselectivity.²⁵ To gauge the applicability of the Fujita–Nagao protocol in the present context, (*S*)-**9** was condensed with propionaldehyde and afforded **10** in 95% yield (Scheme 2). The absolute

Scheme 2



^a Sn(OTf)₂, *N*-ethylpiperidine, CH₂Cl₂, –78 °C, 2 h; CH₃CH₂CHO, –78 °C, 1 h (95%).

configuration of **10** was ascertained by X-ray crystallographic analysis (Figure 1).

Oxidative cleavage of the double bond in **11**,²⁰ best accomplished under Lemieux–Johnson conditions,²⁷ furnished aldehyde **12** (Scheme 3). Union of **12** with (*S*)-**9** led to highly stereocontrolled introduction of two new stereogenic centers under the absolute control of the 1,3-thiazolidine-2-thione as previously demonstrated. The transformation of **13** into the Weinreb amide²⁸ occurred in 97% yield without any detectable epimerization. Following formation of the TBS ether, reduction to give aldehyde **14** proceeded quantitatively upon treatment with Dibal-H in THF at –78 °C. At this juncture, recourse was made to a second aldol reaction, now involving **14**, to establish absolute configuration properly at C14 and C15. To this end, ketone **8** was first converted to its *Z*-enolsilane according to the Masamune protocol.²⁹ This regio- and stereoselective transformation led to **15** (Scheme 4). Our expectation was that coupling of **14**





Figure 1. ORTEP diagram of **10**.

to **15** under catalysis by boron trifluoride etherate at low temperature would proceed in a *syn*-stereoselective manner to set the substituents at C15 and C16 into an anti arrangement. Related processes are recognized to exhibit a tendency to afford anti-Felkin products predominantly via synclinal transition states.³⁰ In the present instance, the Mukaiyama aldol reaction proceeded in a highly controlled manner to deliver **16** as the only detectable product. The assignment of stereochemistry was addressed by spectroscopic analysis of **16** in C₆D₆ solution at 500 MHz. The *syn* relationship between H14 (δ 2.88) and H15 (δ 4.22) was readily deduced on the basis of the low magnitude (2.8 Hz) of the corresponding coupling constant. Similarly, the significant spin–spin interaction between H15 and H16 (9.2 Hz) unequivocally defined their anti relationship. The ensuing olefination³¹ of ketone **17** with the Tebbe reagent³² conveniently provided the targeted molecule **18**.


A convenient, highly enantioselective route to a major portion of **1** has been brought to successful fruition. Our

Scheme 3



^a OsO₄, NMO, THF, H₂O, rt, 50 min; NaIO₄, rt, 1.5 h (87%). ^b (*S*)-**9**, Sn(OTf)₂, *N*-ethylpiperidine, CH₂Cl₂, –78 °C, 2 h 15 min; **12**, –78 °C, 1 h (96%). ^c Me₃Al in hexanes, MeNH(OMe)·HCl, CH₂Cl₂, THF, –5 °C, 1 h 50 min (95%). ^d TBSOTf, 2,6-lutidine, CH₂Cl₂, –20 °C, 1 h 15 min (88%). ^e (*i*-Bu)₂AlH, THF, –78 °C, 15 min (quant).

Scheme 4



^a (PhMe₂Si)₂NLi, THF, -78 °C, 1 h; TMSCl, -78 °C to rt, 6 h (35%; 100% based on recovered **8**). ^b BF₃·Et₂O, toluene, -78 °C, 1.5 h (67%). ^c SEMCl, (*i*-Pr)₂NEt, Bu₄NI, THF, rt, 2 days (53%). ^d Cp₂Ti(Cl)CH₂AlMe₂, THF, -78 °C to rt, 6 h (23%, 88% based on recovered **17**).

synthetic pathway exploits the very utilitarian capability of tin enolates derived from *N*-acyl-1,3-thiazolidine-2-thiones to control aldol stereoselectivity with minimal regard for matched/mismatched pairing, as well as the many advantages associated with Lewis acid-promoted C–C bond formation between aldehydes and stereodefined enolsilanes. Completion of the synthesis of **1** is being actively pursued.³³

(31) Pine, S. H. *Org. React. (N.Y.)* **1993**, 43, 1.

(32) Tebbe, F. N.; Parshall, G. W.; Reddy, G. S. *J. Am. Chem. Soc.* **1978**, 100, 3611.

(33) The structure assigned to each new compound is in full accord with its IR, 300 MHz, ¹H NMR, 75 MHz ¹³C NMR, and high-resolution MS spectra.

Acknowledgment. We thank the Eli Lilly Company for financial support.

Supporting Information Available: Tables of X-ray crystal data, bond lengths and angles, and positional and anisotropic displacement parameters for **10**. This material is available free of charge via the Internet at <http://pubs.acs.org>. This information can also be obtained on request from The Director, Cambridge Crystallographic Data Centre, University Chemical Laboratory, Lensfield Road, Cambridge CB2 1EW, U.K.

OL0000049